New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePT-141 (Bremelanotide) vs Adamax

PT-141 (Bremelanotide) vs Adamax

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Cognitive Enhancement
Adamax
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Half-Life
2–3 hours
Estimated 1-3 hours (short; peptide degradation)
Admin Route
SubQ
Subcutaneous, Intranasal (research)
Research
Typical Dose
0.5–1.75 mg
200-400 mcg per dose
Frequency
As needed (not daily)
Once daily or every other day
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
Stacks With